You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Details for Patent: 8,080,580


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,080,580
Title:Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Abstract: Compounds of Formula (I) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors). ##STR00001##
Inventor(s): Mascitti; Vincent (Groton, CT), Collman; Benjamin M. (Ledyard, CT)
Assignee: Pfizer Inc. (New York, NY)
Application Number:12/546,306
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,080,580
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Drugs Protected by US Patent 8,080,580

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Msd Sub Merck SEGLUROMET ertugliflozin; metformin hydrochloride TABLET;ORAL 209806-002 Dec 19, 2017 RX Yes No ⤷  Sign Up ⤷  Sign Up Y Y AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES ⤷  Sign Up
Msd Sub Merck SEGLUROMET ertugliflozin; metformin hydrochloride TABLET;ORAL 209806-001 Dec 19, 2017 RX Yes No ⤷  Sign Up ⤷  Sign Up Y Y AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES ⤷  Sign Up
Msd Sub Merck SEGLUROMET ertugliflozin; metformin hydrochloride TABLET;ORAL 209806-004 Dec 19, 2017 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES ⤷  Sign Up
Msd Sub Merck SEGLUROMET ertugliflozin; metformin hydrochloride TABLET;ORAL 209806-003 Dec 19, 2017 RX Yes No ⤷  Sign Up ⤷  Sign Up Y Y AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,080,580

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2334687 ⤷  Sign Up 122018000070 Germany ⤷  Sign Up
European Patent Office 2334687 ⤷  Sign Up 300943 Netherlands ⤷  Sign Up
European Patent Office 2334687 ⤷  Sign Up LUC00079 Luxembourg ⤷  Sign Up
European Patent Office 2334687 ⤷  Sign Up 2018C/027 Belgium ⤷  Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.